The Life Sciences team advised Relay Therapeutics, Inc. (Nasdaq: RLAY) on its $460 million upsized initial public offering, the third-largest biotech industry IPO to date. The company offered 23,000,000 shares of its common stock, including 3,000,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $20.00 per share. 

Relay is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, Relay Therapeutics aims to effectively drug protein targets that have previously been intractable, with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology.

The Goodwin team was led by Bill Collins, Mitch Bloom and Gaby Morales-Rivera and included Jason Goldfarb, Nikhil Sethi, Janet Andolina, Matt Dunay,  Kathleen Kean, Theresa Kavanaugh, Sarah Bock, Jennifer Fay, Caroline Galiatsos, Roger Cohen, and Alex Varond.

For more details, read the press release and article in S&P Global Market Intelligence and Endpoints.